LTAS
RPRX icon

Linden Thomas Advisory Services’s Royalty Pharma RPRX Stock Holding History

Linden Thomas Advisory Services’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-33,674
Closed -$1.02M – 477
2024
Q1 		$1.02M Buy
33,674
+2,699
+9% +$79.6K 0.16% 255
2023
Q4 		$870K Buy
30,975
+2,152
+7% +$59.1K 0.16% 258
2023
Q3 		$782K Buy
+28,823
New +$856K 0.17% 255

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Linden Thomas Advisory Services's RPRX Position: Q2 2024 in Review

Linden Thomas Advisory Services sold out of Royalty Pharma (RPRX) in Q2 2024, closing a stake of 33,674 shares — an estimated $1.02M sold.

Linden Thomas Advisory Services first reported a position in RPRX in Q3 2023 and held it in 3 quarters. The position peaked at $1.02M in Q1 2024. 378 funds tracked by Wall St. Rank hold RPRX as of Q2 2024.

  • Linden Thomas Advisory Services reported no remaining Royalty Pharma position as of Q2 2024 after selling out during the quarter.
  • Linden Thomas Advisory Services sold 33,674 Royalty Pharma shares in Q2 2024, an estimated $1.02M.
  • Linden Thomas Advisory Services first reported a position in Royalty Pharma in Q3 2023 and held it in 3 quarters.
  • Linden Thomas Advisory Services's Royalty Pharma position peaked at $1.02M in Q1 2024.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2024.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2024, filed 10 Jul 2024.